HCA Healthcare (NYSE:HCA) Issues FY 2025 Earnings Guidance

HCA Healthcare (NYSE:HCA) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 24.050-25.850 for the period, compared to the consensus EPS estimate of 24.610. The company issued revenue guidance of $72.8 billion-$75.8 billion, compared to the consensus revenue estimate of $74.8 billion.

HCA Healthcare Stock Performance

NYSE HCA opened at $312.51 on Friday. The company has a market capitalization of $79.16 billion, a price-to-earnings ratio of 14.03, a PEG ratio of 1.09 and a beta of 1.64. HCA Healthcare has a twelve month low of $279.93 and a twelve month high of $417.14. The stock has a fifty day simple moving average of $313.49 and a 200 day simple moving average of $352.62. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 48.71.

HCA Healthcare (NYSE:HCA) last announced its earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, beating the consensus estimate of $6.03 by $0.19. HCA Healthcare had a return on equity of 520.98% and a net margin of 8.52%. During the same period in the previous year, the firm earned $5.90 EPS. Sell-side analysts expect that HCA Healthcare will post 21.75 EPS for the current year.

Analysts Set New Price Targets

HCA has been the subject of several research analyst reports. StockNews.com lowered HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Truist Financial cut their price target on HCA Healthcare from $430.00 to $390.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $392.00 price target on shares of HCA Healthcare in a report on Tuesday, October 1st. Morgan Stanley lowered their price objective on shares of HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Finally, Oppenheimer raised their price target on shares of HCA Healthcare from $390.00 to $400.00 and gave the company an “outperform” rating in a research report on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $385.27.

Insiders Place Their Bets

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the sale, the insider now owns 6,843 shares of the company’s stock, valued at $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Phillip G. Billington sold 3,897 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $350.00, for a total value of $1,363,950.00. Following the transaction, the senior vice president now owns 52,702 shares in the company, valued at approximately $18,445,700. The trade was a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.